

March 3, 2015



DelMar Pharmaceuticals to Present at the 27th Annual ROTH Conference on March 10, 2015

- Live Presentation with Audio Webcast on Tuesday, March 10th at 5:00 p.m. Pacific Time / 8:00 p.m. Eastern Time -

VANCOUVER, British Columbia and MENLO PARK, Calif., March 3, 2015 /PRNewswire/ - [DelMar Pharmaceuticals, Inc.](#) (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting at the [27th Annual ROTH Conference](#) being held March 8-11, 2015, at The Ritz-Carlton, Laguna Niguel, in Dana Point, California.

Jeffrey Bacha, DelMar's president and CEO, will present on Tuesday, March 10, 2015, at 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time). Mr. Bacha will provide a corporate overview and an update on the progress of the dose-escalation portion of the Phase 1/2 clinical trial of [VAL-083](#) (dianhydrogalactitol) for the treatment of refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.

A live audio webcast of the presentation will be available by accessing the DelMar's [SLR Calendar](#) in the [Investors](#) section of the Company's website (www.DelMarPharma.com). A webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

About VAL-083

[VAL-083](#) is a first-in-class, small-molecule chemotherapeutic with a unique mechanism of action. In more than 40 Phase 1 and 2 clinical studies sponsored by the National Cancer Institute, VAL-083 has shown safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas. As a potential treatment for glioblastoma, VAL-083's mechanism of action is unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar[®] (temozolomide). DelMar is currently studying VAL-083 in a Phase 1/2 clinical trial for patients with refractory glioblastoma multiforme.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in

development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha, President & CEO (604) 629-5989 or Amato & Partners LLC, Investor Relations admin@amatoandpartners.com. Follow us on Twitter [@DelMarPharma](https://twitter.com/DelMarPharma) or on Facebook Facebook.com/delmarpharma.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-present-at-the-27th-annual-roth-conference-on-march-10-2015-300044183.html>

SOURCE DelMar Pharmaceuticals, Inc.